Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

Taking Vitamin D Supplements May Not Improve Bone Health

Linda Carroll  |  

(Reuters Health)—Vitamin D supplementation may not improve bone density or prevent fractures and falls in adults, a large new analysis suggests. After combining data from 81 randomized controlled trials, researchers found no bone benefits from supplementing the vitamin, according to the report in The Lancet Diabetes & Endocrinology, online October 4. “Our results show that…

FDA Expands Safety Measures for Immediate Release Opioids

  |  

The FDA has expanded the new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to include immediate release opioids. The program, which also includes extended release and long acting opioids, will provide education to prescribers and healthcare professionals…

Depression Tied to Arthritis Pain

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Depressed individuals over age 50 should be screened for arthritis pain because the two conditions often occur together, worsening mental and physical health outcomes, researchers say. “Our findings shed light on the high rates of self-reported, doctor-diagnosed arthritis in U.S. older adults with varying degrees of depression,” Dr. Jessica Brooks of the…

TNFi Exposure in Utero

  |  

Vinet et al. evaluated the risk of serious infections in children of women with RA exposed to TNFi’s in the gestational period compared with unexposed offspring of women with RA, as well as with children from the general population. Although the research did not demonstrate a marked excess risk for serious infections, the authors could not exclude a differential risk according to specific TNFi, with infliximab potentially resulting in a threefold increase in the risk of serious infections compared with other TNFi’s. More studies are needed…

Advocates for Arthritis Push for Policy Changes at Annual Event

  |  

The ACR advocates on behalf of the rheumatology community throughout the year, but it’s always especially exciting when patients join our efforts in Washington, D.C. Close to 100 patients, rheumatologists and representatives of the broader interprofessional team traveled to our nation’s capital this week to participate in the ACR’s annual Advocates for Arthritis event. Participants…

Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

  |  

AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  

Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…